Clinical Trial

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate whether HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion with venetoclax-containing regimens (microtransplant, MST) could improve survival in adult patients with newly diagnosed acute myeloid leukemia (AML).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-14.
Trial Details
NCT Number NCT07078591
Lead Sponsor Beijing 302 Hospital
Conditions Acute Myeloid Leukemia
Enrollment 50 participants
Start Date 2025-06-20
Primary Completion 2030-06 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2025-07-28